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ABSTRACT
Objective: The present study was done to understand the effect of formulation variables on the quality of orodispersible films using quality by design 
(QbD) approach as mentioned in ICH Q8 (R2) guideline.
Methods: A definitive screening design of experiments (DoE) was used to identify and classify the critical formulation variables affecting critical 
quality attributes (CQA) using 2×2 factorial design. Based on prescreening study, the critical formulation variables, i.e. concentration of film-forming 
polymer and plasticizers (propylene glycol and polyethylene glycol 400 [PEG 400]) were kept in the range of 1.5–2.5% w/w and 0.5–1% v/v, 
respectively. A total of eight laboratory-scale formulations were prepared which were provided by DoE using solvent casting method. These batches 
were evaluated for CQA’s, i.e. mechanical properties such as folding endurance (FD) and disintegration time (DT). Data were analyzed for elucidating 
interactions between two variables and for providing a predictive model for the process. Finally, the drug was incorporated into optimized batches, 
and these were evaluated for in vitro dissolution study in simulated saliva (pH 6.8) as well as their mechanical properties.
Results: The results suggested that the concentration of film-forming polymer and plasticizer was critical to manufacture orodispersible film with 
desired CQA, i.e. mechanical property (FD [>150 folds]) and DT (<60 s). The percent drug release, FD, and DT of optimized Formulation I (hydroxypropyl 
methylcellulose [HPMC] E5 (2%) and propylene glycol [0.15 mL]) were found to be 82.13%±0.260 (in 15 min), 164±2, and 49±1.5 s, respectively, and 
for optimized Formulation II (HPMC E5 [2%] and PEG 400 [0.15 mL]) was found to be 64.26%±2.026 (in 15 min) and 218±6 and 55±4 s, respectively.
Conclusion: From the results, it has been found that the percentage drug release of naratriptan hydrochloride containing propylene glycol as a 
plasticizer was greater than the formulation containing PEG 400 as plasticizer. From this, we concluded that QbD is very much useful approach to get 
an optimized formulation in an economic and faster way in comparison to traditional method (hit and trail methods). The futuristic application of the 
film will involve the management of an acute migraine.
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INTRODUCTION
In the past few years, the pharmaceutical company or researchers 
mainly focus on those drug delivery systems, which provide faster 
onset of action of drug, enhanced bioavailability, and high patient 
compliance [1]. Nowadays, the best route for the administration of 
drug is oral as compared to other drug delivery route [2]. From all the 
dosage forms available in the market, there is a one solid dosage form, 
which has a high potential, and it also, fulfills these requirements are 
orodispersible films [3]. According to the Borges et al., the patients 
who are suffering from dysphagia, orodispersible film approach is very 
beneficial and useful for the delivery of the drug. Orodispersible film 
offers some features such as portability, stability, and flexibility, which 
confer superiority over the orodispersible capsules, and tablets [4]. 
An orodispersible films are very thin with the shape of postage stamp 
containing active pharmaceutical ingredient, polymers, and with or 
without plasticizers. An orodispersible film when placed onto the 
mucosal surface instantly gets wetted with saliva. After wetting it 
rapidly disintegrate and release its medicament [5]. The drawbacks of 
orodispersible films include moisture sensitivity, extreme temperature, 
high loading dose problem, and requirement of costly packaging [6].








The pharmaceutical quality by design (QbD) is a systemic approach 
to development that begins with the predefined objectives and 
emphasizes product and process understanding and process control, 
based on sound science and quality risk management [8].
Critical process parameter (CPP) whose variability has an impact on a 
critical quality attributes (CQA) and therefore should be monitored or 
controlled to ensure the process produces the desired quality.
CQA are chemical, physical, biological, and microbiological attributes 
that can be defined, measured, and continually monitored to ensure 
final product outputs remain within acceptable quality limits.
Acute migraine is a disabling disorder characterized by moderate to 
severe throbbing, pulsating pain often associated with photophobia, 
phonophobia, nausea, and vomiting. It worsens with day to day 
activity of patient [9,10]. An untreated migraine attack can past 
for	 4–72	 h	 [11,12].	 Sexual	 dimorphism	 is	 reported	 in	 migraine,	
i.e.	prevalence	ratio	among	men	and	women	is	3:7	[13,14].
There are two approaches through which we can manage migraine, 
i.e. symptomatic therapy which further divided into two, i.e. use of non-
specific drugs and specific drugs (ergot alkaloids and triptans), depends 
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on the efficacy of migraine attack. The second approach is preventative 
therapy, in which doctor gives the suggestion about daily life routine to 
the patients [15]. There are majorly conventional tablets available in 
the market, which is used for management of an acute migraine. Our 
film has more advantage over that as discussed above.
Naratriptan is a serotonin 5-HT1B/1D receptor agonist and is used for 
the treatment of acute migraine. Activation of 5-HT1B receptor, which 
is present on the vascular smooth muscles, causes vasoconstriction 
of smooth muscles [16]. Activation of 5-HT1D which is located on the 
sensory trigeminal terminals inhibits the release of sensory and 
vasoactive	neuropeptides	and	vasodilator	transmitters	[17,18].
MATERIALS AND METHODS
Naratriptan hydrochloride was obtained as gift samples from Apotex 
Pharmachem Pvt., Ltd., India. Hydroxypropyl methylcellulose (HPMC) 
E5, propylene glycol, and polyethylene glycol 400 (PEG 400) were 
purchased from Loba Chemie. All other chemicals and reagents used 
were of analytical grade.
Preparation of orodispersible placebo film
Solvent	 casting	 method	 was	 used	 for	 the	 preparation	 of	 film.	 In	 this	
method initially, all the polymers are dissolved in the suitable solvent, 
and the drug and other additives are mixed in the other beaker containing 
suitable solvent. After that mix both the solution and stir it for some time. 
Then, the solution is subjected to the sonicator to eradicate the air bubble. 
Finally, that solution is transferred into Teflon or glass Petri plate and then 
placed in an oven for overnight at 50–60°C for drying. Peel out the film 
and kept in the desiccator till further use (Fig. 1) [19]. The film was cut in 
a piece of 3×1 cm2 for further evaluation with the help of surgical blade.
QbD approach to develop orodispersible placebo film
A definitive screening design of experiments (DoE) was used to identify 
and classify the CPP affecting CQA using 2×2 factorial design. In this 
research study, we have considered CPP is concentration of HPMC E5, 
propylene glycol, and PEG 400. From the literature, we get to know 
about the concentration of above through which, good film was obtained 
with desired outcomes. If we increase the concentration of polymer, then 
there would be problem takes place during pouring, and resulting film 
is too thick. If we decrease the concentration, film becomes too thin, 
and it does not give desired outcomes. The main purpose of focusing 
disintegration time (DT) and folding endurance (FD) as CQA because if 
the DT is more than 60 s, then there may be chances that patient may split 
it. This is reason we get eight batches after applying DoE (Figs. 2 and 3).
Evaluation of orodispersible placebo film
FD
It is the number of times a film could be folded manually at the same 
place without getting crack on it. It was checked by folding each film 
repeatedly at the same place until it breaks or folding it for 150 times 
whichever is less [20].
In vitro DT
It tells about the disintegration and dissolution features of the film. 
Films from each batch of dimensions 3 cm × 1 cm2 was put in a Petri 
dish (6.5 cm diameter) having 25 ml of simulated saliva, maintained at 
37°C,	with	agitation	at	every	10	s.	The	DT	was	recorded	when	the	film	
starts to break or disintegrate [21].
Preparation of optimized orodispersible film containing 
naratriptan hydrochloride
After analyzing the observations of 8 batches in DoE (Table 1); finally, we 
got the optimized concentration of polymer and plasticizer for the final 
formulation in which we had incorporated naratriptan hydrochloride. 
Accurately weigh 10 mg of drug and placed into the beaker containing 
10 mL of water. Then, the solution was subjected to magnetic stirrer 
for dissolving the drug completely followed by addition of remaining 
additives. Further, the procedure was same as discussed above for the 
preparation of orodispersible placebo film.
Fig. 1: Solvent casting method
Fig. 2: Contour plot (optimization concentrations of 
hydroxypropyl methylcellulose E5 [2% w/v] and propylene glycol 
(0.15 mL)]
Fig. 3: Contour plot (optimization concentrations of 
hydroxypropyl methylcellulose E5 [2%w/v] and polyethylene 
glycol 400 [0.15 mL])
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Evaluation of optimized formulation (Table 2)
FD and in vitro DT
The folding endurance (FD) and in vitro disintegration time (DT) 
studies were performed as per the procedures mentioned under the 
title - Evaluation of orodispersible placebo film.
In vitro drug release
The in vitro drug release was carried out in 250 ml of simulated 
saliva	 as	 dissolution	 medium	 using	 USP	 dissolution	 apparatus	 I,	
maintained	 at	 37±0.5°C	with	 100	 rpm.	 10	ml	 samples	were	 taken	
at different predetermined time intervals, and the same amount 
of fresh dissolution medium maintained at same temperature was 
added to maintain the sink condition in the dissolution vessel. 
Samples	were	passed	through	0.45	µm	membrane	filter	after	suitable 
dilutions, if required and then analyzed spectrophotometrically. It 
was conducted 3 times for each film formulation, and the average 
value was taken [22].
RESULTS
The resultant formulation was transparent with a smooth texture. The 
outcomes of the resultant formulation are being tabulated below:
Optimized Formulation I contains the drug, hydroxypropyl 
methylcellulose (HPMC) E5 and propylene glycol, optimized 
Formulation II contains the drug, HPMC E5, and polyethylene glycol 400
CONCLUSION AND DISCUSSION
From the literature review, we came to know that using the concentration 
of polymer between 1.5% w/v and 2.5%w/v and plasticizer 0.1–
0.2 mL, we will get the required FD, i.e. >150 folds and DT <1 min. 
We used same concentration of polymer and plasticizer, after that 
applied QbD. After applying QbD, we got an optimized formulations 
which show the required outcomes, i.e. FD >150 folds and DT <1 min 
(Table 3 and 4). We had done the in vitro dissolution study of both 
optimized batches, and from the results (Table 5 and 6), it had been 
concluded the percentage drug release of naratriptan hydrochloride 
in the optimized Formulation I after 15 min was >80% (Fig. 4). Hence, 
from this, we selected Formulation I for further study. From this, we 
concluded that QbD is very much useful approach to get an optimized 
formulation.
Fig. 4: In vitro drug release comparison between optimized 
Formulation I and optimized Formulation II. 
Table 2: Results of prepared placebo films (n=3)









deviation, FD: Folding endurance
Table 3: Comparison between predicted and observed value of 
optimized formulation of HPMC E5 and Propylene glycol (n=3)
Responses Predicted value Observed value (mean±SD)
DT (s) 46.75 49±1.5
FD (no.) 158.5 164±2
HPMC:	Hydroxypropyl	methylcellulose,	SD:	Standard	deviation,	FD:	Folding	
endurance
Table 4: Comparison between predicted and observed value of 
optimized formulation of HPMC E5 and PEG 400 (n=3)
Responses Predicted value Observed value (mean±SD)
DT (s) 58 55±4
FD (no.) 222 218±6
PEG 400: Polyethylene glycol 400, HPMC: Hydroxypropyl methylcellulose, 
SD:	Standard	deviation,	FD:	Folding	endurance
Table 5: In vitro drug release of the film of HPMC E5 and propylene glycol (n=3)




Corrected conc  
(μg/mL) (mean±SD)
Amount of drug (mg)  
(mean±SD)
% drug release  
(mean±SD)
0 0 0 0 0 0
2 0.101±0.002 0.4803±0.020 0.4803±0.020 0.1200±0.005 41.29±1.730
5 0.119±0.003 0.6619±0.030 0.6715±0.030 0.1676±0.007 57.75±2.650
10 0.131±0.001 0.7830±0.010 0.8024±0.004 0.200±0.001 69.01±0.340
15 0.145±0.001 0.9243±0.010 0.9549±0.006 0.238v0.002 82.13±0.260
20 0.149±0.002 0.9646±0.020 1.021±0.020 0.2552±0.005 87.81±1.840
25 0.156±0.002 1.0353±0.020 1.130±0.010 0.2826±0.004 97.21±1.980
30 0.160±0.001 1.0756±0.010 1.1723±0.010 0.2929±0.002 100.82±1.050
SD:	Standard	deviation,	HPMC:	Hydroxypropyl	methylcellulose











F1 1.5 0.1 -
F2 1.5 0.2 -
F3 2.5 0.1 -
F4 2.5 0.2 -
F5 1.5 - 0.2
F6 2.5 - 0.1
F7 2.5 - 0.2
F8 1.5 - 0.1
HPMC: Hydroxypropyl methylcellulose, PEG 400: Polyethylene glycol 400
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Table 6: In vitro drug release of the film of HPMC E5 and PEG 400 (n=3)






Amount of drug (mg)  
(mean±SD)
% drug release  
(mean±SD)
0 0 0 0 0 0
2 0.095±0.003 0.4195±0.030 0.4195±0.030 0.1048±0.007 32.74±2.380
5 0.110±0.002 0.5778±0.020 0.5861±0.021 0.1465±0.005 45.74±1.716
10 0.120±0.001 0.6720±0.010 0.6919±0.011 0.1729±0.002 53.99±0.871
15 0.132±0.002 0.7931±0.020 0.8479±0.021 0.2065±0.005 64.26±2.026
20 0.144±0.003 0.9142±0.030 0.9634±0.031 0.2408±0.008 75.18±2.499
25 0.160±0.002 1.0754±0.020 1.1427±0.022 0.2856±0.005 89.17±1.745
30 0.172±0.001 1.196±0.010 1.2851±0.012 0.3213±0.003 100.32±1.018
SD:	Standard	deviation,	HPMC:	Hydroxypropyl	methylcellulose,	PEG	400:	Polyethylene	glycol	400
